Deferasirox Supplier in Nigeria
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer to NAFDAC-registered importers.
Supply & Market
Nigeria has one of the highest sickle-cell disease (SCD) prevalences globally - meaning significant populations require chronic transfusion and iron chelation. NAFDAC (National Agency for Food & Drug Administration and Control) regulates pharmaceutical products and operates a WHO-PQ aligned dossier-assessment pathway. Taj Pharma supplies DEFRATAJ Deferasirox dispersible tablets into Nigeria through registered distributors and NAFDAC-listed products.
Supply options to Nigeria include CIF Lagos / Apapa port and Lagos / Abuja airfreight for smaller consignments. Sample dispatch by express courier typically 4-6 business days. English-language packaging is standard; GS1 DataMatrix serialisation can be added where local pharmacy-chain / tender requirement exists. Safety-stock allocation for Nigerian partners ensures bridging supply during registration and post-launch ramp-up.
NAFDAC registration follows a full-dossier pathway including Module 3 quality data, stability (ICH Q1A Zone IVb recommended for West Africa), bioequivalence, CoPP on WHO format and manufacturer GMP certificate. Expedited review pathways may apply for WHO-PQ listed products or products meeting public-health priority criteria. Our RA team supports deficiency responses and post-approval variations. Timeline typically 9-18 months.